Syros Pharmaceuticals Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer,

Penny stocks are incredibly volatile financial vehicles not for the faint of heart. That said, you might win big with these offerings.

The stock price of Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) increased by 17.17% yesterday. This is why it happened.

Former penny stocks on Reddit you might've overlooked this month The post Reddit Penny Stocks You Might've Missed In May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it plans to host a three-par

Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q1 2021 Results - Earnings Call Transcript

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 58.18% and 58.26%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the s

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conferen

It has been 10 months since we last looked at a developmental concern named Syros Pharmaceuticals and we promised we would keep an eye on developments.

Syros Pharmaceuticals, Inc. (SYRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further s

Catherine Wood ( Trades , Portfolio )'s ARK Investment Management has revealed a large reduction in the Organovo Holdings Inc. (NASDAQ:ONVO) position alongside a small reduction in the Syros Pharmaceu

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2020 Results - Earnings Call Transcript

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -12.96% and 78.06%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for t

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conferen